
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 15, 2018

XENON PHARMACEUTICALS INC.

(Exact name of Registrant as Specified in Its Charter)

Canada
(State or Other Jurisdiction
of Incorporation)

001-36687
(Commission File Number)

98-0661854
(IRS Employer
Identification No.)

200-3650 Gilmore Way
Burnaby, British Columbia, Canada
(Address of Principal Executive Offices)

V5G 4W8
(Zip Code)

Registrant's Telephone Number, Including Area Code: (604) 484-3300

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 8.01 Other Events

On March 15, 2018, Xenon Pharmaceuticals Inc. (the “Company”) announced the meeting, record date and certain other information relating to its 2018 annual meeting of shareholders pursuant to a filing submitted to the System for Electronic Document Analysis and Retrieval (“SEDAR”) in Canada.

A copy of the filing submitted to SEDAR is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

| <u>Exhibit Number</u> | <u>Description</u> |
|------------------------------|---|
| 99.1 | <u>SEDAR filing submitted March 15, 2018.</u> |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Xenon Pharmaceuticals Inc.

Date: March 15, 2018

By: _____
/s/ Ian Mortimer
Ian Mortimer
President & Chief Financial Officer



Craig Colosso
Relationship Manager

American Stock Transfer & Trust Company, LLC
Charlotte, North Carolina

Tel: 718.921.8337
Email: ccolosso@amstock.com

www.amstock.com

March 15, 2018

Alberta Securities Commission

British Columbia Securities Commission

Ontario Securities Commission

RE: Xenon Pharmaceuticals Inc.

Pursuant to a request from the above-mentioned reporting issuer, we wish to advise you of the following information in connection with its Annual Meeting of Shareholders:

| | |
|---|---------------|
| Date of meeting: | June 4, 2018 |
| Record date for notice: | April 9, 2018 |
| Record date for voting: | April 9, 2018 |
| Beneficial ownership determination date: | April 9, 2018 |
| Securities entitled to notice: | Common Shares |
| Securities entitled to vote: | Common Shares |
| Issuer mailing directly to non objecting beneficial owners: | No |
| Issuer will pay for objecting beneficial owner material distribution: | Yes |
| Issuer using notice-and-access for registered investors: | No |
| Issuer using notice-and-access for non-registered investors: | No |
| Notice-and-access stratification criteria: | N/A |

Yours very truly,

/s/ Craig Colosso

Craig Colosso
Relationship Manager